Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Nephrology
•
Transplant nephrology
How do you distinguish TMA caused by CNI toxicity versus antibody mediated rejection in a kidney transplant patient?
Related Questions
Should all kidney transplant patients be started on statin therapy post operatively given their increased risk of CVD?
When do you recommend genetic testing prior to kidney transplantation for a patient with ESKD secondary to FSGS?
How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?
Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?
What is your approach to management of tremors in a kidney transplant recipient who is taking a CNI for immunosuppression?
Do you routinely use markers or tests other than serum creatinine when estimating GFR to determine if patients with liver failure, not on dialysis, meet criteria for a simultaneous liver-kidney transplant?
When do you use ambulatory blood pressure monitoring to assess hypertension in a living kidney donor candidate?
How do you approach the management of a kidney transplant recipient who develops de novo donor-specific antibodies but shows no clinical signs of rejection or graft dysfunction?
What is your approach to dose adjusting mycophenolate in a kidney transplant recipient who is transitioned from tacrolimus to cyclosporine?
Do you recommend periodically testing for anti-GBM antibody in patients with ESKD secondary to Alport's syndrome who are status post kidney transplantation?
